These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30006773)

  • 41. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.
    Altcheh J; Moscatelli G; Mastrantonio G; Moroni S; Giglio N; Marson ME; Ballering G; Bisio M; Koren G; García-Bournissen F
    PLoS Negl Trop Dis; 2014 May; 8(5):e2907. PubMed ID: 24853169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.
    Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA
    Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
    Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
    Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heart rate variability in chronic Chagas patients before and after treatment with benznidazole.
    Oliveira LF; Silva VJ; Lages-Silva E; Molina RJ; Fuzissaki J; Niederhaur S; Prata A; Correia D
    Auton Neurosci; 2010 Dec; 158(1-2):118-22. PubMed ID: 20558113
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions.
    Correia JPR; Costa ACD; Rocha EA; Quidute ARP; Cândido DDS; Ponciano ÂMS; Fonteles MMF; Oliveira MF
    Rev Soc Bras Med Trop; 2017; 50(3):334-340. PubMed ID: 28700051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Benznidazole and chronic Chagas disease].
    Manigot DA
    Medicina (B Aires); 1984; 44(1):105-6. PubMed ID: 6443011
    [No Abstract]   [Full Text] [Related]  

  • 50. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
    Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
    Kratz JM; Garcia Bournissen F; Forsyth CJ; Sosa-Estani S
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):943-957. PubMed ID: 30111183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease.
    Cevey ÁC; Mirkin GA; Donato M; Rada MJ; Penas FN; Gelpi RJ; Goren NB
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):378-387. PubMed ID: 29040909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial.
    Viotti R; Vigliano C; Lococo B; Bertocchi G; Petti M; Alvarez MG; Postan M; Armenti A
    Ann Intern Med; 2006 May; 144(10):724-34. PubMed ID: 16702588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
    Cardoso CS; Ribeiro ALP; Oliveira CDL; Oliveira LC; Ferreira AM; Bierrenbach AL; Silva JLP; Colosimo EA; Ferreira JE; Lee TH; Busch MP; Reingold AL; Sabino EC
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006814. PubMed ID: 30383777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
    Morillo CA; Marin-Neto JA; Avezum A; Sosa-Estani S; Rassi A; Rosas F; Villena E; Quiroz R; Bonilla R; Britto C; Guhl F; Velazquez E; Bonilla L; Meeks B; Rao-Melacini P; Pogue J; Mattos A; Lazdins J; Rassi A; Connolly SJ; Yusuf S;
    N Engl J Med; 2015 Oct; 373(14):1295-306. PubMed ID: 26323937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole.
    Teixeira AR; Córdoba JC; Souto Maior I; Solórzano E
    Am J Trop Med Hyg; 1990 Aug; 43(2):146-58. PubMed ID: 2117856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy.
    Antinori S; Grande R; Bianco R; Traversi L; Cogliati C; Torzillo D; Repetto E; Corbellino M; Milazzo L; Galli M; Galimberti L
    Clin Infect Dis; 2015 Jun; 60(12):1873-5. PubMed ID: 25805302
    [No Abstract]   [Full Text] [Related]  

  • 58. An evaluation of benznidazole as a Chagas disease therapeutic.
    Caldas IS; Santos EG; Novaes RD
    Expert Opin Pharmacother; 2019 Oct; 20(15):1797-1807. PubMed ID: 31456439
    [No Abstract]   [Full Text] [Related]  

  • 59. Potential new clinical therapies for Chagas disease.
    Bustamante JM; Tarleton RL
    Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.